INTRODUCTION
This analysis focuses on the changing landscape of the commercial environment in the global arthritis market and investigates key strategies
required to succeed. Analysis of company portfolio strategies and product positioning provides in-depth knowledge of how specific company strategies
result in varying levels of commercial returns.
SCOPE OF THE REPORT
- Detailed case studies featuring company portfolio, product development and launch strategies of leading global players in arthritis
- Global sales data for the major classes used in treating arthritis - NSAIDs, DMARDs, HA viscosupplements and steroids
- Event-based forecasts to 2011 for the top selling drugs in each class
- SWOT analyses of key arthritis drugs, along with 12-month event screens - providing detailed knowledge of events specific to each product
REPORT HIGHLIGHTS
Despite facing adversity in the past year, including continued negative publicity surrounding the cardiovascular side effect profile of Vioxx and
the delayed launch of Arcoxia, Merck will remain a strong competitor for Pfizer/Pharmacia in the future and the COX-II inhibitor class will continue
to flourish through 2011.
The alleviation of Enbrel's supply shortage through the new manufacturing facility approved in early 2003 will enable
Amgen to regain a significant portion of sales lost to J&J's Remicade although Humira is presenting formidable competition for both drugs.
KEY REASONS TO BUY THIS REPORT
- Target current and future growth areas through identification of the strongest product lifecycle and pricing strategies
- Learn from case studies analyzing details of the most successful drug launches in the arthritis market
- Plan future product positioning through utilization of event-based forecasts for all major arthritis drugs
View Cart
